10419-59-7

Upstream product

• 1660-94-2 Tetraethyl methylenediphosphonate 
• 100-39-0 benzyl bromide 
• 124810-56-6 diethyl 1-hydroxy-2-phenylethylphosphonate 
• 762-04-9 phosphonic acid diethyl ester 
• 37465-31-9 1,1-bis(diethylphosphono)ethylene 
• 98-80-6 phenylboronic acid 

Downstream Products

• 1254063-28-9 C₂₆H₄₄O₆P₂ 
• 1337993-69-7 2-phenylethylidynetrisphosphonic acid hexaethyl ester 
• 10596-19-7 Benzylmethylen-diphosphonsaeure 

Relevant academic research and scientific papers

Solid-liquid two-phase alkylation of tetraethyl methylenebisphosphonate under microwave irradiation

Optimum conditions for the solid-liquid phase alkylation of tetraethyl methylenebisphosphonate are dependent on the nature of the alkyl halide. The benzylation with benzyl bromide takes place efficiently in boiling acetonitrile in the presence of potassiu

Copper-mediated 1,4-conjugate addition of boronic acids and indoles to vinylidenebisphosphonate leading to gem-bisphosphonates as potential antiresorption bone drugs

A wide range of gem-bisphosphonate tetraethyl esters as precursors for bisphosphonic acids, which are potent inhibitors of bone resorption, bearing alkyl, aryl, and indole substituents in the β position were prepared through the CuII-catalyzed 1,4-conjugate addition of boronic acids and indoles to vinylidenebisphosphonate tetraethyl ester.

Water enhanced synthesis of gem-bisphosphonates via Rh(i) mediated 1,4-conjugate addition of aryl boronic acids to vinylidenebisphosphonate esters

A new synthetic method characterized by low environmental impact for the synthesis of a wide range of gem-bisphosphonates bearing aryl substituents in β position as potential anti-resorption species to contrast osteoporosis is reported. The pivotal role p

Synthesis and reactivity of alkyl-1,1,1-trisphosphonate esters

The α-trisphosphonic acid esters provide a unique spatial arrangement of three phosphonate groups and may represent an attractive motif for inhibitors of enzymes that utilize di- or triphosphate substrates. To advance studies of this unique functionality,

METAL COMPLEX COMPOUND, CANCER THERAPEUTIC COMPOSITION COMPRISING THE METAL COMPLEX COMPOUND AS ACTIVE INGREDIENT, AND INTERMEDIATE FOR PRODUCTION OF THE METAL COMPLEX COMPOUND

A metal complex compound which exhibits a high degree of adsorption to bone or inhibition of cell growth, and is highly effective for therapy of a cancer metastasized to bone and therapy of the primary carcinoma thereof; a therapeutic agent composition for a cancer containing as an active ingredient the metal complex compound or a physiologically acceptable salt thereof; and an intermediate for the metal complex compound are provided. More concretely, a metal complex compound represented by the following General Formula (1): (wherein R1 independently represents C1-C10 alkyl which may be branched or have a substituent; or a C3-C30 cyclic group which may have a substituent; and X represents CHR2, an oxygen atom or NR5); a therapeutic agent composition for a cancer containing it as an active ingredient; and an intermediate for the metal complex compound are provided.

Synthesis and biological evaluation of a series of aromatic bisphosphonates

Geminal bisphosphonates display varied biological activity depending on the nature of the substituents on the central carbon atom. For example, the nitrogenous bisphosphonates zoledronate and risedronate inhibit the enzyme farnesyl diphosphate synthase wh

Studies on organophosphorus compounds 68. A new and facile synthetic approach to alkylidenebisphosphonates

Condensation of aldehydes with diethyl phosphite followed by sulfonylation of the α-hydroxy group formed with methanesulfonyl chloride and subsequent substitution by another molecule of diethylphosphite provides corresponding alkylidenebisphosphonates in one-pot procedure with good yield.

gem-Diphosphonate and gem-phosphonate-phosphate compounds with specific high density lipoprotein inducing activity

New diphosphonate compounds and related derivatives were synthesized and investigated for their activity in specifically inducing plasma high density lipoproteins (HDL) and high density lipoprotein cholesterol (HDL-C) in normal rats. The screening of nume